Fostering Growth of Next Generation Technology and Services for Clinical Trials

Our goal is to build a company that excels in today’s clinical trial landscape of personalized medicine, multiple trial modalities, and increased patient centricity.

Technology solutions have had a tremendously positive impact on the quality and efficiency of clinical trials. As the number and type of solutions have propagated, the burden on sponsors, sites, and patients has increased. There is opportunity to consolidate platforms to address critical pain points around the patient and site experience and ultimately deliver drugs to patients faster.
  • Patient recruitment and retention
  • Patient concierge and payment
  • DCT and Hybrid trial execution
  • RTSM and logistics
  • eClinical data collection
    (eConsent, eCOA, eSource, wearables, EDC)
  • Data analysis and visualization
  • Real World Evidence (RWE)
Fostering Growth of Next Generation Technology and Services for Clinical Trials

Our goal is to build a company that excels in today’s clinical trial landscape of personalized medicine, multiple trial modalities, and increased patient centricity.

Technology solutions have had a tremendously positive impact on the quality and efficiency of clinical trials. As the number and type of solutions have propagated, the burden on sponsors, sites, and patients has increased. There is opportunity to consolidate platforms to address critical pain points around the patient and site experience and ultimately deliver drugs to patients faster.
  • Patient recruitment and retention
  • Patient concierge and payment
  • DCT and Hybrid trial execution
  • RTSM and logistics
  • eClinical data collection
    (eConsent, eCOA, eSource, wearables, EDC)
  • Data analysis and visualization
  • Real World Evidence (RWE)

Harpula Leadership: Experience is the Difference

News Update: Jack Shannon Joins Harpula as Chief Commercial Officer. Read more...
Steve Powell
Founder and CEO
Read Bio
Connect on LinkedIn
Mary Hickey Mattes
Founder and COO
Read Bio
Connect on LinkedIn
We recognize the opportunity to build a more coordinated technology solution through acquisition and organic growth. Harpula will invest in companies and assets in the technology-enabled pharmaceutical solutions industry to improve the clinical trial experience for patients, sites, and sponsors. Our years of experience and leadership in clinical trial execution and its related technology will provide the ongoing guidance and oversight necessary to succeed.  

The Harpula – GTCR Partnership

Harpula is backed by Chicago-based private equity firm GTCR, with 40+ years of experience and more than $26 billion under management. GTCR brings their pioneering The Leaders Strategy™ and core domain experience in healthcare and pharma-tech to bear for Harpula, with their focus on investing in transformative growth in their portfolio companies.

“We look forward to working together with Steve and Mary to build a leading tech-enabled pharmaceutical solutions company,” said Ben Daverman, Managing Director and Co-Head of Healthcare at GTCR. “They have an exceptional track record in the pharmaceutical services space with experience across CRO and eClinical organizations. Their backgrounds, industry expertise and strategic vision make them ideal partners as GTCR commits to build a platform in this attractive industry.”
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $24 billion in over 270 companies, and the firm currently manages over $26 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
Click here to view the press release

Contact Us

Steve Powell
Founder and CEO
Steve is a dynamic and proven executive with 30+ years of global CRO, eClinical and Pharma/Biotech industry experience. He has led companies of all sizes, directing strategy across every facet of Phase I-IV clinical research, including operations, business development, and technology, as well as acquisitions and integrations. Steve was the recipient of the PharmaVoice Top 100 Most Inspiring People award in 2017 for Technology Innovation with a Patient-Focus.

As Chief Executive Officer of Synteract, Steve drove the development and implementation of Synteract’s strategic direction, providing the focus to drive its growth and to meet its goal to become the CRO of choice for Emerging Biopharma companies. Over his 4+ years in the role at Synteract, the company defined and expanded it's leading CRO market position; grew top and bottom line financial metrics by double digits; culminating in a successful acquisition by Syneos Health in Dec 2020, returning a 4+X return to their Private Equity owners.

Steve’s previous leadership roles include 8 years at PRA Health Sciences as part of the Executive team and as EVP for Clinical Informatics and Late Phase Services. Previously, he held senior management roles at INC Research and Quintiles for over 12 years. Steve also provided executive leadership at Exco InTouch and ERT, following his passion of technology, data and patient engagement. As President and COO of Exco InTouch, Steve oversaw all aspects of operational delivery and technology development, while at ERT, he managed an advanced data and analytics platform for trial execution.

Throughout his career, Steve has been responsible for designing and leading operational growth, identifying and integrating new technologies, processes and services. He brings a team-oriented approach to leadership, with an extensive mix of operational and technology expertise, and a keen focus on customer delivery.
Mary Hickey Mattes
Founder and COO
Mary is an energetic and passionate leader with twenty five years of experience in the clinical trial research industry. Now a founding partner at Harpula, where she is looking to foster the growth of next-generation clinical trial technology, her clinical research path was built through multi-national CROs. In these roles, she was responsible for execution of operational, technology and regulatory requirements for Phase I-IV trials. As the Chief Operating Officer at Synteract, Mary contributed to the growth and success of the company through process improvement, team development, and customer delivery resulting in double digit revenue and profitability growth and a successful 4X sale to Syneos Health.

Mary's passion is working with people to attain lofty goals, and she has loved defining and managing teams from 20 to 500 people to achieve deliverables as well as quality, revenue, and profitability targets. Mary's broad-based skills in identification and implementation of clinical technology solutions have developed by identifying and implementing solutions for CRO and SMO needs in growth environments. Mary has shown proven leadership in organizational change, team development, and process creation as well as defining and developing global teams to meet the demands of today’s clinical research environment.
Jack Shannon
CCO
Jack is a highly experienced executive leader with 22 years of CRO, technology, and pharma/biotech industry experience within global commercial organizations. During his time in the industry, Jack has helped to evolve and scale clinical technology companies, small to midsize biotech, large pharma, and large to midsize CROs.

Most recently, Jack was the Chief Commercial Officer for Virb, the first end-to-end talent as a service platform that bridges the new talent gap in Clinical Research through innovative source, train, and deploy technologies. 

Prior to his experience at Virb, Jack was the Executive Vice President, Business Development at Syneos Health and helped lead the post acquisition integration of Synteract, where he was the Chief Commercial Officer at the time of acquisition. At Synteract, Jack was responsible for managing the global sales team in North America and Europe, as well as the global marketing and brand awareness team where he oversaw a rebranding initiative and overall market acquisition strategies prior to being acquired by Syneos. In addition, as a member of the Executive Leadership team, he took part in the due diligence and acquisition of two companies that became part of Synteract. During Jack's tenure at Synteract, the company enjoyed 4x growth, and became an industry standout in the CRO market.

Before joining Synteract, Jack led the Global BioPharma Sales Team for Chiltern (NA, EU, APAC), helping to establish and lead market growth and sales strategies in the BioPharma segment. During his 3 years at Chiltern, the BioPharma sales team had significant growth in market share and sales. Chiltern then went through a successful sales process with Labcorp.

Prior to that, he spent 7 years at PRA Health Sciences, where he most recently was Executive Director, Business Development, managing three of PRA’s strategic partnerships and the inside sales team. He also held several senior level roles in business development and proposals over an 8 year period at Quintiles, now IQVIA.
© 2024 Harpula Holdings, LLC. All rights reserved. Trademarks used herein are trademarks or registered trademarks of Harpula. All other names and brands are trademarks or registered trademarks of their respective companies. Products, services and or offers herein are subject to change without notice. Privacy Policy and Terms of Use. Website design and management: Diseño.com
Contact Us